Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial

OBJECTIVES: Cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with metastatic colorectal cancer with RAS wild-type (RAS wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomised, m...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMJ Open
Autori principali: Wang, Huijuan, Huang, Lingfei, Gao, Peng, Zhu, Zhengyi, Ye, Weifeng, Ding, Haiying, Fang, Luo
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Health Economics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7044820/
https://ncbi.nlm.nih.gov/pubmed/32051297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2019-030738
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi